Less than a year after withdrawing a proposed initial public offering, TolerRx Inc. dipped into the private markets, raising $31 million in a Series D round. (BioWorld Today)

LONDON - Evolutec Group plc raised £9.5 million (US$17.7 million) in a secondary fund raising that was more than two times oversubscribed, just seven months after its initial public offering was pegged back from a hoped-for £7.5 million to £5.1 million. (BioWorld International)